A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration.

Research output: Contribution to journalArticle

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{972d8962952e490084817daa10bfe0e8,
title = "A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration.",
abstract = "BACKGROUND AND AIMS: Hepatitis C virus (HCV) causes progressive liver disease and is a major risk factor for the development of hepatocellular carcinoma (HCC). However, the role of infection in HCC pathogenesis is poorly understood. We investigated the effect(s) of HCV infection and viral glycoprotein expression on hepatoma biology to gain insights into the development of HCV associated HCC. METHODS: We assessed the effect(s) of HCV and viral glycoprotein expression on hepatoma polarity, migration and invasion. RESULTS: HCV glycoproteins perturb tight and adherens junction protein expression, increasehepatoma migration and expression of epithelial to mesenchymal transition markers Snail and Twist via stabilizing hypoxia inducible factor-1α (HIF-1α). HIF-1α regulates many genes involved in tumor growth and metastasis, including vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-β). Neutralization of growth factors show different roles for VEGF and TGF-β in regulating hepatoma polarity and migration, respectively. Importantly, we confirmed these observations in virus infectedhepatoma and primary human hepatocytes. Inhibition of HIF-1α reversed the effect(s) of infection and glycoprotein expression on hepatoma permeability and migration and significantly reduced HCV replication, demonstrating a dual role for HIF-1α in the cellular processes that are deregulated in many human cancers and in the viral life cycle. CONCLUSIONS: These data provide new insights into the cancer-promoting effects of HCV infection on HCC migration and offer new approaches for treatment.",
author = "Garrick Wilson and Claire Brimacombe and Ian Rowe and Gary Reynolds and Nicola Fletcher and Zacharenia Stamataki and Ricky Bhogal and M Sim{\~o}es and M Ashcroft and Simon Afford and RR Mitry and A Dhawan and CJ Mee and Stefan Hubscher and Peter Balfe and Jane McKeating",
year = "2011",
month = dec,
day = "15",
doi = "10.1016/j.jhep.2011.11.018",
language = "English",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration.

AU - Wilson, Garrick

AU - Brimacombe, Claire

AU - Rowe, Ian

AU - Reynolds, Gary

AU - Fletcher, Nicola

AU - Stamataki, Zacharenia

AU - Bhogal, Ricky

AU - Simões, M

AU - Ashcroft, M

AU - Afford, Simon

AU - Mitry, RR

AU - Dhawan, A

AU - Mee, CJ

AU - Hubscher, Stefan

AU - Balfe, Peter

AU - McKeating, Jane

PY - 2011/12/15

Y1 - 2011/12/15

N2 - BACKGROUND AND AIMS: Hepatitis C virus (HCV) causes progressive liver disease and is a major risk factor for the development of hepatocellular carcinoma (HCC). However, the role of infection in HCC pathogenesis is poorly understood. We investigated the effect(s) of HCV infection and viral glycoprotein expression on hepatoma biology to gain insights into the development of HCV associated HCC. METHODS: We assessed the effect(s) of HCV and viral glycoprotein expression on hepatoma polarity, migration and invasion. RESULTS: HCV glycoproteins perturb tight and adherens junction protein expression, increasehepatoma migration and expression of epithelial to mesenchymal transition markers Snail and Twist via stabilizing hypoxia inducible factor-1α (HIF-1α). HIF-1α regulates many genes involved in tumor growth and metastasis, including vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-β). Neutralization of growth factors show different roles for VEGF and TGF-β in regulating hepatoma polarity and migration, respectively. Importantly, we confirmed these observations in virus infectedhepatoma and primary human hepatocytes. Inhibition of HIF-1α reversed the effect(s) of infection and glycoprotein expression on hepatoma permeability and migration and significantly reduced HCV replication, demonstrating a dual role for HIF-1α in the cellular processes that are deregulated in many human cancers and in the viral life cycle. CONCLUSIONS: These data provide new insights into the cancer-promoting effects of HCV infection on HCC migration and offer new approaches for treatment.

AB - BACKGROUND AND AIMS: Hepatitis C virus (HCV) causes progressive liver disease and is a major risk factor for the development of hepatocellular carcinoma (HCC). However, the role of infection in HCC pathogenesis is poorly understood. We investigated the effect(s) of HCV infection and viral glycoprotein expression on hepatoma biology to gain insights into the development of HCV associated HCC. METHODS: We assessed the effect(s) of HCV and viral glycoprotein expression on hepatoma polarity, migration and invasion. RESULTS: HCV glycoproteins perturb tight and adherens junction protein expression, increasehepatoma migration and expression of epithelial to mesenchymal transition markers Snail and Twist via stabilizing hypoxia inducible factor-1α (HIF-1α). HIF-1α regulates many genes involved in tumor growth and metastasis, including vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-β). Neutralization of growth factors show different roles for VEGF and TGF-β in regulating hepatoma polarity and migration, respectively. Importantly, we confirmed these observations in virus infectedhepatoma and primary human hepatocytes. Inhibition of HIF-1α reversed the effect(s) of infection and glycoprotein expression on hepatoma permeability and migration and significantly reduced HCV replication, demonstrating a dual role for HIF-1α in the cellular processes that are deregulated in many human cancers and in the viral life cycle. CONCLUSIONS: These data provide new insights into the cancer-promoting effects of HCV infection on HCC migration and offer new approaches for treatment.

U2 - 10.1016/j.jhep.2011.11.018

DO - 10.1016/j.jhep.2011.11.018

M3 - Article

C2 - 22178269

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

ER -